Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)

被引:0
作者
Lee, Minji K. [1 ]
Mitchell, Sandra A. [2 ]
Basch, Ethan [3 ]
Mazza, Gina L. [4 ]
Langlais, Blake T. [5 ]
Thanarajasingam, Gita [6 ]
Ginos, Brenda F. [4 ]
Rogak, Lauren [5 ]
Meek, Eric A. [5 ]
Jansen, Jennifer [3 ]
Deal, Allison M. [3 ]
Carr, Philip [3 ]
Blinder, Victoria S. [7 ]
Jonsson, Mattias [3 ]
Mody, Gita N. [3 ]
Mendoza, Tito R. [2 ]
Bennett, Antonia V. [3 ]
Schrag, Deborah [7 ]
Dueck, Amylou C. [4 ]
机构
[1] Mayo Clin, Alliance Fdn Trials Stat & Data Ctr, 200 1st Ave SW, Rochester, MN 55902 USA
[2] NCI, Bethesda, MD USA
[3] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[4] Mayo Clin, Alliance Fdn Trials Stat & Data Ctr, Scottsdale, AZ USA
[5] Mayo Clin, Dept Quantitat Hlth Sci, Scottsdale, AZ USA
[6] Mayo Clin, Div Hematol, Rochester, MN USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY USA
关键词
Individual-level meaningful change threshold; PRO-CTCAE; Meaningful worsening; MINIMAL IMPORTANT CHANGE; EORTC QLQ-C30; CANCER; VALIDITY; SCORE;
D O I
10.1007/s11136-024-03819-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background We derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE (R)) items and their composite scores. Methods We used two data sources, the PRO-TECT trial (Alliance AFT-39) that collected PRO-CTCAE data from adults with advanced cancer at 26 United States (U.S.) community oncology practices and the PRO-CTCAE validation study that collected PRO-CTCAE data from adults undergoing chemotherapy or radiation therapy at nine U.S. cancer centers or community oncology practices. Both studies administered selected PRO-CTCAE items and EORTC QLQ-C30 scales. Conceptually, relevant QLQ-C30 domains were used as anchors to estimate meaningful change thresholds for deterioration in corresponding PRO-CTCAE items and their composite scores. Items or composites with |rho| >= 0.30 correlation with QLQ-C30 scales were included. Changes in PRO-CTCAE scores and composites were estimated for patients who met or exceeded a 10-point deterioration on the corresponding QLQ-C30 scale. Change scores were computed between baseline and the 3-month timepoint in PRO-TECT, and in the PRO-CTCAE validation study between baseline and a single follow-up visit that occurred between 1 and 7 weeks later. For each PRO-CTCAE item, change scores could range from - 4 to 4; for a composite, change scores could range from - 3 to 3. Results Change scores in QLQ-C30 and PRO-CTCAE were available in 406 and 792 patients in PRO-TECT and the validation study, respectively. Across QLQ-C30 scales, the proportion of patients with a 10-point or greater worsening on QLQ-C30 ranged from 15 to 30% in the PRO-TECT data and 13% to 34% in the validation data. Across PRO-CTCAE items, anchor-based meaningful change estimates for deterioration ranged from 0.05 to 0.30 (mean 0.19) in the PRO-TECT data and from 0.19 to 0.53 (mean 0.36) in the validation data. For composites, they ranged from 0.06 to 0.27 (mean 0.17) in the PRO-TECT data and 0.22 to 0.51 (mean 0.37) in the validation data. Conclusion In both datasets, the minimal meaningful individual-level change threshold for worsening was one point for all items and composite scores.
引用
收藏
页码:495 / 507
页数:13
相关论文
共 28 条
  • [1] What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales
    Atkinson, Thomas M.
    Hay, Jennifer L.
    Dueck, Amylou C.
    Mitchell, Sandra A.
    Mendoza, Tito R.
    Rogak, Lauren J.
    Minasian, Lori M.
    Basch, Ethan
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2018, 55 (03) : E3 - E6
  • [2] Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer A Randomized Clinical Trial
    Basch, Ethan
    Schrag, Deborah
    Henson, Sydney
    Jansen, Jennifer
    Ginos, Brenda
    Stover, Angela M.
    Carr, Philip
    Spears, Patricia A.
    Jonsson, Mattias
    Deal, Allison M.
    Bennett, Antonia, V
    Thanarajasingam, Gita
    Rogak, Lauren J.
    Reeve, Bryce B.
    Snyder, Claire
    Bruner, Deborah
    Cella, David
    Kottschade, Lisa A.
    Perlmutter, Jane
    Geoghegan, Cindy
    Samuel-Ryals, Cleo A.
    Given, Barbara
    Mazza, Gina L.
    Miller, Robert
    Strasser, Jon F.
    Zylla, Dylan M.
    Weiss, Anna
    Blinder, Victoria S.
    Dueck, Amylou C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (24): : 2413 - 2422
  • [3] Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Basch, Ethan
    Becker, Claus
    Rogak, Lauren J.
    Schrag, Deborah
    Reeve, Bryce B.
    Spears, Patricia
    Smith, Mary Lou
    Gounder, Mrinal M.
    Mahoney, Michelle R.
    Schwartz, Gary K.
    Bennett, Antonia, V
    Mendoza, Tito R.
    Cleeland, Charles S.
    Sloan, Jeff A.
    Bruner, Deborah Watkins
    Schwab, Gisela
    Atkinson, Thomas M.
    Thanarajasingam, Gita
    Bertagnolli, Monica M.
    Dueck, Amylou C.
    [J]. CLINICAL TRIALS, 2021, 18 (01) : 104 - 114
  • [4] Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Basch, Ethan
    Reeve, Bryce B.
    Mitchell, Sandra A.
    Clauser, Steven B.
    Minasian, Lori M.
    Dueck, Amylou C.
    Mendoza, Tito R.
    Hay, Jennifer
    Atkinson, Thomas M.
    Abernethy, Amy P.
    Bruner, Deborah W.
    Cleeland, Charles S.
    Sloan, Jeff A.
    Chilukuri, Ram
    Baumgartner, Paul
    Denicoff, Andrea
    St Germain, Diane
    O'Mara, Ann M.
    Chen, Alice
    Kelaghan, Joseph
    Bennett, Antonia V.
    Sit, Laura
    Rogak, Lauren
    Barz, Allison
    Paul, Diane B.
    Schrag, Deborah
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09):
  • [5] Important differences and meaningful changes for the functional assessment of cancer therapy-cognitive function (FACT-COG)
    Bell M.L.
    Dhillon H.M.
    Bray V.J.
    Vardy J.L.
    [J]. Journal of Patient-Reported Outcomes, 2 (1)
  • [6] Perspectives of patients with advanced or metastatic non-small cell lung cancer on symptoms, impacts on daily activities, and thresholds for meaningful change: a qualitative research study
    Cardellino, Anna
    Shah, Manasee
    Hanlon, Jennifer
    Kelly, Kimberly
    Martin, Alexandra
    de Climens, Aude Roborel
    Taiyari, Sara
    Stojadinovic, Alexander
    [J]. FRONTIERS IN PSYCHOLOGY, 2023, 14
  • [7] The Symptom Burden of Cancer: Evidence for a Core Set of Cancer-Related and Treatment-Related Symptoms From the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns Study
    Cleeland, Charles S.
    Zhao, Fengmin
    Chang, Victor T.
    Sloan, Jeff A.
    O'Mara, Ann M.
    Gilman, Paul B.
    Weiss, Matthias
    Mendoza, Tito R.
    Lee, Ju-Whei
    Fisch, Michael J.
    [J]. CANCER, 2013, 119 (24) : 4333 - 4340
  • [8] How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales
    Cocks, Kim
    Buchanan, Jacqueline
    [J]. QUALITY OF LIFE RESEARCH, 2023, 32 (05) : 1247 - 1253
  • [9] Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
    Coon, Cheryl D.
    Schlichting, Michael
    Zhang, Xinke
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2022, 15 (06) : 691 - 702
  • [10] Interpreting Change in Scores on Patient-Reported Outcome Instruments
    Coon, Cheryl D.
    Cappelleri, Joseph C.
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (01) : 22 - 29